Quest Diagnostics and LabCorp, two of the biggest laboratory diagnostics outfits around, will not accept any blood samples from patients suspected of having the Ebola virus.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
For the medical diagnostics industry, 2014 is looking like a seesaw in terms of venture investment trends.
As concern mounts over the deadly Ebola epidemic, French scientists are developing a diagnostic tool that works similar to a home pregnancy test and can quickly identify the virus through a tiny fluid sample.
Silicon Valley startup InSilixa roped in $13M in financing to develop its innovative molecular diagnostic tests for drug-resistant bacteria and infections.
Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
A subsidiary of French in vitro diagnostics giant bioMérieux gained Medicare coverage for a new breast cancer test, a vital milestone necessary to compete in today's market.
Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.
From Our Sister Sites
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
Denmark-based Novo Nordisk said on Friday that it had received a subpoena from a U.S. Attorney who wants some info about its manufacturing operations at a plant in Kalundborg. But the company said it really has no idea why.